Ekman S - Search Results

1

Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells.

Wu X, Sooman L, Lennartsson J, Bergström S, Bergqvist M, Gullbo J, Ekman S. Wu X, et al. Among authors: ekman s. Int J Oncol. 2013 Jan;42(1):297-304. doi: 10.3892/ijo.2012.1710. Epub 2012 Nov 20. Int J Oncol. 2013. PMID: 23174948

2

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.

Strömberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, Lennartsson J, Hellman U, Carlson K, Osterborg A, Vanderkerken K, Nilsson K, Jernberg-Wiklund H. Strömberg T, et al. Among authors: ekman s. Blood. 2006 Jan 15;107(2):669-78. doi: 10.1182/blood-2005-01-0306. Epub 2005 Sep 15. Blood. 2006. PMID: 16166596 Free article.

3

Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment.

Eriksson P, Brattström D, Hesselius P, Larsson A, Bergström S, Ekman S, Goike H, Wagenius G, Brodin O, Bergqvist M. Eriksson P, et al. Among authors: ekman s. Neoplasma. 2006;53(4):285-90. Neoplasma. 2006. PMID: 16830054

4

Activation of growth factor receptors in esophageal cancer--implications for therapy.

Ekman S, Bergqvist M, Heldin CH, Lennartsson J. Ekman S, et al. Oncologist. 2007 Oct;12(10):1165-77. doi: 10.1634/theoncologist.12-10-1165. Oncologist. 2007. PMID: 17962610 Free article. Review.

5

Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies.

Ekman S, Eriksson P, Bergström S, Johansson P, Goike H, Gullbo J, Henriksson R, Larsson A, Bergqvist M. Ekman S, et al. Anticancer Res. 2007 Sep-Oct;27(5B):3545-53. Anticancer Res. 2007. PMID: 17972516 Free article. Review.

6

Esophageal cancer: current and emerging therapy modalities.

Ekman S, Dreilich M, Lennartsson J, Wallner B, Brattström D, Sundbom M, Bergqvist M. Ekman S, et al. Expert Rev Anticancer Ther. 2008 Sep;8(9):1433-48. doi: 10.1586/14737140.8.9.1433. Expert Rev Anticancer Ther. 2008. PMID: 18759695 Review.

7

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.

Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Ekman S. Wu X, et al. Among authors: ekman s. Br J Cancer. 2009 Jan 27;100(2):334-43. doi: 10.1038/sj.bjc.6604855. Epub 2009 Jan 13. Br J Cancer. 2009. PMID: 19142186 Free PMC article.

8

Impact of age at diagnosis on prognosis and treatment in laryngeal cancer.

Reizenstein JA, Bergström SN, Holmberg L, Linder A, Ekman S, Blomquist E, Lödén B, Holmqvist M, Hellström K, Nilsson CO, Brattström D, Bergqvist M. Reizenstein JA, et al. Among authors: ekman s. Head Neck. 2010 Aug;32(8):1062-8. doi: 10.1002/hed.21292. Head Neck. 2010. PMID: 19953624

9

Hsp90 as a therapeutic target in patients with oesophageal carcinoma.

Ekman S, Bergqvist M, Tell R, Bergström S, Lennartsson J. Ekman S, et al. Expert Opin Ther Targets. 2010 Mar;14(3):317-28. doi: 10.1517/14728221003621278. Expert Opin Ther Targets. 2010. PMID: 20148718 Review.

10

Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy.

Holgersson G, Ekman S, Reizenstein J, Bergqvist M, Pontén F, Uhlén M, Magnusson K, Jonnalagadda P, Asplund A, Strömberg S, Linder A, Blomquist E, Liljeholm M, Lödén B, Hellström K, Bergström S. Holgersson G, et al. Among authors: ekman s. Cancer Genomics Proteomics. 2010 Jan-Feb;7(1):1-7. Cancer Genomics Proteomics. 2010. PMID: 20181625

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

331 results

Search Page